Liu E, Marin D, Banerjee P, et al. - This study was conducted to investigate the efficacy of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. Researchers gave HLA-mismatched anti-CD19 CAR-NK cells obtained from cord blood to 11 patients with relapsed or refractory CD19-positive cancers (non-Hodgkin’s lymphoma or chronic lymphocytic leukemia [CLL]). The evidence showed that the administration of CAR-NK cells was not correlated with the increase of cytokine release syndrome, neurotoxicity, or graft-vs-host disease, and there was no development in the levels of inflammatory cytokines, including interleukin-6, over baseline. It was reported that a majority had a response to treatment with CAR-NK cells without the growth of major toxic effects among 11 individuals with relapsed or refractory CD19-positive cancers.